{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:07:32Z","timestamp":1792048052278,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,9,7]],"date-time":"2006-09-07T00:00:00Z","timestamp":1157587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24\u2010week double\u2010blind placebo\u2010controlled study. Primary efficacy measures were the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS\u2010cog) and Alzheimer's Disease Cooperative Study\u2013Clinician's Global Impression of Change (ADCS\u2010CGIC). Secondary efficacy measures included activities of daily living, behavioral symptoms, and executive and attentional functions. Patients were stratified according to the presence of visual hallucinations at baseline. The study included 188 visual hallucinators (118 on rivastigmine, 70 on placebo) and 348 nonvisual hallucinators (239 on rivastigmine, 109 on placebo). Rivastigmine provided benefits in both visual hallucinators and nonvisual hallucinators. Absolute responses to rivastigmine on the ADAS\u2010cog were comparable over 6 months, although rivastigmine\u2013placebo differences tended to be larger in visual hallucinators (4.27; <jats:italic>P<\/jats:italic> = 0.002) than in nonhallucinators (2.09; <jats:italic>P<\/jats:italic> = 0.015). On the ADCS\u2010CGIC, differences between rivastigmine and placebo were 0.5 in visual hallucinators (<jats:italic>P<\/jats:italic> = 0.030) and 0.3 in nonhallucinators (<jats:italic>P<\/jats:italic> = 0.111). Rivastigmine provided benefits on all secondary efficacy measures, and placebo declines and treatment differences were more marked in visual hallucinators. Adverse events were reported more frequently by rivastigmine\u2010treated patients, although this difference was less marked in visual hallucinators. Visual hallucinations appear to predict more rapid decline and possibly greater therapeutic benefit from rivastigmine treatment in PDD. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21077","type":"journal-article","created":{"date-parts":[[2006,9,7]],"date-time":"2006-09-07T13:51:51Z","timestamp":1157637111000},"page":"1899-1907","source":"Crossref","is-referenced-by-count":235,"title":["Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease"],"prefix":"10.1002","volume":"21","author":[{"given":"David","family":"Burn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Emre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McKeith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Paul","family":"De Deyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanchieh","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10219"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00351-X"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.4.733"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068010.82167.CF"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb06891.x"},{"key":"e_1_2_6_7_2","first-page":"A435","article-title":"Long\u2010term prognosis of hallucinating Parkinson's disease patients treated with quetiapine or clozapine","volume":"58","author":"Juncos JL","year":"2002","journal-title":"Neurology"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.524"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb00217.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610297004523"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb03162.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.6.745"},{"key":"e_1_2_6_14_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"issue":"2","key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko D","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_6_18_2","volume-title":"Delis\u2013Kaplan Executive Function System","author":"Delis DC","year":"2001"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.930060208"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.389"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0514"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-8610(04)70069-9"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.1.19"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.5.596"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21077","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:02:51Z","timestamp":1760958171000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,7]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1002\/mds.21077"],"URL":"https:\/\/doi.org\/10.1002\/mds.21077","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,7]]}}}